Atrial Natriuretic Hormone, Vessel Dilator, Long Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease Circulating Prolactin Concentrations

D. L. Vesely; G. I. San Miguel; I. Hassan; D. D. Schocken

doi:10.1055/s-2002-32137

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2002; 34(5): 245-249
DOI: 10.1055/s-2002-32137

Original Clinical

Atrial Natriuretic Hormone, Vessel Dilator, Long Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease Circulating Prolactin Concentrations

D. L. Vesely ^1, ^2, ³ , G. I. San Miguel ^1, ^2, ³ , I. Hassan^1, ^2, ³ , D. D. Schocken^1, ²

¹University of South Florida Cardiac Hormone Center, Tampa, USA
²Departments of Internal Medicine, Physiology and Biophysics, University of South Florida Health Sciences Center, Tampa, USA
³James A. Haley Veterans Medical Center, Tampa, USA

Abstract

The present investigation was designed to test whether four cardiac hormones - long acting natriuretic hormone, vessel dilator, kaliuretic hormone and atrial natriuretic hormone decrease the circulating concentration of prolactin in humans (n = 30). Vessel dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic hormone decreased the circulating concentration of prolactin to 3 %, 31 %, 27 %, and 23 % of control values, respectively, at the end of their infusions when infused at concentrations of 100 ng/kg body weight per minute for 60 minutes (p < 0.001 for each). Vessel dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic hormone had sustained effects on modulating prolactin’s concentrations, with circulating concentrations of 1 %, 64 %, 28 %, and 2 % of control values (p < 0.001) 3 hours after stopping their respective infusions. These results suggest that there are four circulating prolactin-inhibitory hormones in addition to the hypothalamic mediators, dopamine and corticotropin-releasing hormone, which modulate prolactin release. These peptide hormones’ ability to decrease circulating prolactin concentrations may be mediated in part by dopamine and in part by their demonstrated ability to decrease corticotropin-releasing hormone concentrations, which stimulate prolactin release.

Key words

Prolactin-Inhibitory Hormones - Corticotropin-Releasing Hormone - Hypothalamus - Natriuretic Hormones

Volltext

Referenzen

References

1 Ohashi M, Fujio N, Nawata H, Kato K, Matsuo H, Ibayashi H. Effect of α-human atrial natriuretic polypeptide on anterior pituitary function in men. Endocr J. 1987; 34 659-663
2 Foresta C, Caretto A, Mioni R, Betterle C, Scandellari C. Evidence of immunoreactive human atrial peptides in human anterior pituitary cells. Horm Metab Res. 1988; 20 376-377
3 Foresta C, DeCarlo E, Mioni R, Zorzi M, Scandellari C. Evidence for a dopaminergic involvement in the inhibitory effect of alpha human natriuretic peptide on prolactin in man. Horm Metab Res. 1989; 21 630-634
4 Wiedemann K, Herzog L, Kellner M. Atrial natriuretic hormone inhibits corticotropin-releasing hormone-induced prolactin release in man. J Psychr Res. 1995; 29 51-58
5 Vesely D L. Atrial Natriuretic Hormones. Englewood Cliffs Prentice Hall. 1992; 1-256
6 Standaert D G, Needleman P, Day M L, Weigand R, Krause J E. Expression of the gene for preproatriopeptin in the central nervous system of the rat. Mol Brain Res. 1988; 4 7-13
7 Martin D R, Pevahouse J B, Trigg D J, Vesely D L, Buerkert J E. Three peptides from the ANF prohormone NH₂-terminuteus are natriuretic and/or kaliuretic. Am J Physiol. 1990; 258 F1401-F1408
8 Vesely D L, Norris J S, Walters J M, Jespersen R R, Baeyens D A. Atrial natriuretic prohormone peptides 1 - 30, 31 - 67 and 79 - 98 vasodilate the aorta. Biochem Biophys Res Commun. 1987; 148 1540-1548
9 Vesely D L, Douglass M A, Dietz J R, Giordano A T, McCormick M T, Rodriguez-Paz G, Schocken D D. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab. 1994; 78 1128-1134
10 Vesely D L, Douglass M A, Dietz J R, Gower W R , McCormick M T, Rodriguez-Paz G, Schocken D D. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994; 90 1129-1140
11 Vesely D L, Dietz J R, Parks J R, Baig M, McCormick M T, Cintron G, Schocken D D. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation. 1998; 98 323-329
12 Vesely D L, Norsk P, Winters C J, Rico D M, Sallman A L, Epstein M. Increased release of the N-terminal and C -terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med. 1989; 192 230-235
13 Winters C J, Sallman A L, Baker B J, Meadows J, Rico D M, Vesely D L. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation. 1989; 80 438-449
14 Hunter E FM, Kelly P A, Prowse C, Woods R J, Lowry P J. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest. 1998; 58 205-216
15 Ackerman B H, Wyeth R P, Vesely D L, Ngo L, Bissett J K, Winters C H, Sallman A L. Pharmacokinetic characterization of the post-distribution phase of prohormone atrial natriuretic peptides amino acids 1 - 98, 31 - 67, and atrial natriuretic factor during and following rapid right ventricular pacing in dogs. J Clin Pharmacol. 1992; 32 415-421
16 Poulos J E, Gower W R, Sullebarger J T, Fontanet H L, Vesely D L. Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc Res. 1996; 32 909-919
17 Dietz J R, Nazian S J, Vesely D L. Release of ANF, proANF 1 - 98, and proANF 31 - 67 from isolated rat atria by atrial distention. Am J Physiol. 1991; 260 H1774-H1778
18 Ackerman B H, Overton R M, McCormick M T, Schocken D D, Vesely D L. Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans following a one-hour infusion. J Pharmacol Exp Therap. 1997; 282 603-608
19 Schulte H M, Chrousos G P, Gold P W, Oldfield E H, Hoban M C, Cutler G B, Loriaux D L. Corticotropin-releasing factor (CRF): A common link between anterior pituitary and sympathetic responses to stress. Acta Endocrinol. 1983; 102 (Suppl 253) 32-33
20 Vesely D L, San Miguel G I, Hassan I, Schocken D D. Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin-releasing hormone, corticotropin and cortisol. J Clin Endocrinol Metab. 2001; 86 4244-4249
21 Flores C M, Hulihan-Giblin G A, Homby P J, Lumpkin M D, Kellar K J. Partial characterization of the neurotransmitter pathway regulating the in vitro release of prolactin. Neuroendocrinology. 1992; 55 519-528
22 Sampson W K, Bianchi R. Further evidence for a hypothalamic site of action of atrial natriuretic factor: inhibition of prolactin secretion in the conscious rat. Can J Physiol Pharmacol. 1988; 66 301-305
23 Sampson W K, Bianchi R, Mogg R. Evidence for a dopaminergic mechanism for the prolactin inhibitory effect of atrial natriuretic factor. Neuroendocrinology. 1988; 47 268-271
24 Kadowaki K, Hirota K, Koike K, Ohmichi M, Miyake A, Tanizawa O. Atrial and brain natriuretic peptides enhance dopamine accumulation in cultured hypothalamic cells including dopaminergic neurons. Neuroendocrinology. 1992; 56 11-17
25 Nakao K, Katsura G, Mori N, Itoh H, Shiono S, Yamada T, Sugawara A, Sakamoto M, Saito Y, Eigyo M, Matsushita A, Imura H. Inhibitory effect of centrally administered atrial natriuretic polypeptide on brain dopaminergic system in rats. Eur J Pharmacol. 1986; 131 171-177
26 Kawata M, Nakao K, Morii N, Kiso Y, Yamashita H, Imura H, Sano Y. Atrial natriuretic polypeptide: Topographical distribution in the rat brain by radioimmunoassay and immunochemistry. Neuroscience. 1985; 16 521-546
27 Kurihara M, Saavedra J M, Shigematsu K. Localization and characterization of atrial natriuretic peptide binding sites in discrete areas of rat brain and pituitary gland by quantitative autoradiography. Brain Res. 1987; 408 31-39
28 Koch B, Boudjada T, Lutz-Bucher B. Characterization of high affinity receptor sites for atrial natriuretic factor in anterior pituitary gland: evidence for the existence of two receptor forms. Biochem Biophys Res Commun. 1988; 152 904-909
29 Wilcox J N, Augustine A, Goeddel D V, Lowe D G. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol. 1991; 11 3454-3462
30 Grandclement B, Brisson C, Bayard G, Tremblay J, Gossard F, Morel G. Localization of mRNA coding for three subtypes of atrial natriuretic factor (ANF) receptors in rat anterior pituitary gland cells. J Neuroendocrinol. 1995; 7 939-948
31 Gutkowska J, Antunes-Rodrigues J, McCann S M. Atrial natriuretic peptide in brain and pituitary gland. Physiological Rev. 1997; 77 465-515
32 Edwards A V, Ghatei M A, Bloom S R. The effect of splanchnic nerve stimulation on the uptake of atrial natriuretic peptide by the adrenal gland of conscious calves. J Endocrinol Invest. 1990; 13 887-892
33 Duntas L, Bornstein S R, Scherbaum W A, Holst J J. Atrial natriuretic peptide-like immunoreactive material (ANP-LI) is released from the adrenal gland by splanchnic stimulation. Exp & Clin. Endocrinol. 1993; 101 371-373
34 Katznelson L, Klibanski A. Prolactin and its disorders. In: Principles and Practice of Endocrinology and Metabolism. Becker KL (ed) .Philadelphia; J B Lippincott Co. 1995: 140-147
35 Vesely D L, Winters C J, Sallman A L. Prohormone atrial natriuretic peptides 1 - 30 and 31 - 67 increase in hyperthyroidism and decrease in hypothyroidism. Am J Med Sci. 1989; 297 209-215
36 Honbo K S, Herle A JV, Kellett K A. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978; 64 782-787

D. L. Vesely, M.D., Ph.D.

Chief, Endocrinology, Diabetes & Metabolism · James A. Haley Veterans Hospital-151

13000 Bruce B. Downs Blvd. · Tampa, Florida 33612 · USA ·

Telefon: + 1 (813) 972-7624

Fax: + 1 (813) 972-7623

eMail: vesely.david_l@tampa.va.gov